Our Research Associates and Collaborators

The collaborations are as follows:

• Avipero has a risk sharing agreement with Fusion Antibodies for the optimisation of AVI001 (humanisation).
• AVI001 is licenced from Manitoba to Avipero exclusively for all therapeutic uses. The licence is royalties-free with modest milestone payments.
• Option agreement is in place for access to all other beta1(including the anti-infective AVI002 and beta3 integrin hybridomas